BPC-157s shorter half-life means it works in more concentrated bursts, providing high local activity before clearance
Comparing your trajectory to expected semaglutide weight loss timelines helps identify whether your protocol needs adjustment
The high cost of these drugs prevents them from being widely used, especially in areas with lower incomes
1 Like Manoj_Pradhan June 3, 2025, 7:33pm 34 HC bars Dr Reddys, OneSource from selling Wegovys key element in India Delhi High Court bars Dr Reddys and OneSource from selling semaglutide in India, supporting Novo Nordisks patent rights as it fast-tracks Wegovy launch amid growing obesity drug demand rupeshtatiya October 10, 2025, 6:58am 35 Few comments based on how things stand today - (Based on some conferences companies attended, export data, industry scuttlebutt etc.) STRIDES WhatsApp Image 2025-10-10 at 09.48.00_14d1c4811280492 146 KB With Trump making it clear that there will be no tariffs on Generics under section 232, I think one of the biggest sources of uncertainty is gone
However, the phase 3 clinical trials studying the safety and efficacy are yet to be complete